Abstract
Traditionally, the development of drugs has focused on small molecule therapeutics. However, with recent advances in recombinant protein technology the potential of proteins as therapeutics is starting to be realized. Already there are protein drugs on the market, including naturally occurring proteins, engineered proteins and proteins introduced into the patient by way of gene therapy. The next generation of such drugs are likely to be designed molecules, proteins devised from scratch and specifically tailored to have a required 3-dimensional structure and biochemical function. The key to such de novo design is the extensive bioinformatics knowledge that has been obtained from experimentally determined protein structures during the past 40-50 years. The knowledge is far from complete, for example, the protein folding problem has not yet been completely solved. Despite this, bioinformatics plays a crucial role in protein design, as is outlined in this review, and a number of de novo protein structures have been successfully designed in recent years. Some examples of these successes, which are available in the Protein Data Bank, are presented. They suggest that carefully designed protein therapeutics are a genuine prospect for the future.
Keywords: Bioinformatics, Protein Design
Current Pharmaceutical Biotechnology
Title: Bioinformatics and Protein Design
Volume: 3 Issue: 4
Author(s): Roman A. Laskowski and A.W. Edith Chan
Affiliation:
Keywords: Bioinformatics, Protein Design
Abstract: Traditionally, the development of drugs has focused on small molecule therapeutics. However, with recent advances in recombinant protein technology the potential of proteins as therapeutics is starting to be realized. Already there are protein drugs on the market, including naturally occurring proteins, engineered proteins and proteins introduced into the patient by way of gene therapy. The next generation of such drugs are likely to be designed molecules, proteins devised from scratch and specifically tailored to have a required 3-dimensional structure and biochemical function. The key to such de novo design is the extensive bioinformatics knowledge that has been obtained from experimentally determined protein structures during the past 40-50 years. The knowledge is far from complete, for example, the protein folding problem has not yet been completely solved. Despite this, bioinformatics plays a crucial role in protein design, as is outlined in this review, and a number of de novo protein structures have been successfully designed in recent years. Some examples of these successes, which are available in the Protein Data Bank, are presented. They suggest that carefully designed protein therapeutics are a genuine prospect for the future.
Export Options
About this article
Cite this article as:
Laskowski A. Roman and Chan Edith A.W., Bioinformatics and Protein Design, Current Pharmaceutical Biotechnology 2002; 3 (4) . https://dx.doi.org/10.2174/1389201023378157
DOI https://dx.doi.org/10.2174/1389201023378157 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
SIRT1 Deacetylase Activity and the Maintenance of Protein Homeostasis in Response to Stress: An Overview
Protein & Peptide Letters Update on the Regulation of HIPK1, HIPK2 and HIPK3 Protein Kinases by microRNAs
MicroRNA Neuroprotection with Natural Antioxidants and Nutraceuticals in the Context of Brain Cell Degeneration: The Epigenetic Connection
Current Topics in Medicinal Chemistry New Horizons in the Treatment of Neurological Disorders with Tailorable Gold Nanoparticles
Current Drug Metabolism SUMOylation in Neurological Diseases
Current Molecular Medicine The Potential Role of Glycogen Synthase Kinase 3 Inhibitors as Amyotrophic Lateral Sclerosis Pharmacological Therapy
Current Medicinal Chemistry Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration
Current Neuropharmacology Connection between JAK/STAT and PPARγ Signaling During the Progression of Multiple Sclerosis: Insights into the Modulation of T-Cells and Immune Responses in the Brain
Current Molecular Pharmacology Assessing Glutamatergic Function and Dysfunction in Peripheral Tissues
Current Medicinal Chemistry Astrocyte-Microglia Cooperation in the Expression of a Pro-Inflammatory Phenotype
CNS & Neurological Disorders - Drug Targets Recent Advances and Patents for Nerve Scaffold Biomaterials and their Use for Local, Non-Viral Delivery of Growth Factors and Nucleic Acids
Recent Patents on Biomedical Engineering (Discontinued) Potential Therapeutic Targets for Neurodegenerative Diseases: Lessons Learned from Calorie Restriction
Current Drug Targets Role of Antioxidants in Redox Regulation of Diabetic Cardiovascular Complications
Current Pharmaceutical Biotechnology Misoprostol Reverse Hippocampal Neuron Cyclooxygenase-2 Downstream Signaling Imbalance in Aluminum-Overload Rats
Current Alzheimer Research A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure
Current Vascular Pharmacology Effects of Synthetic Peptides on the Inflammatory Response and their Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Meet Our Editorial Board Member
Recent Patents on CNS Drug Discovery (Discontinued) Targeting Microglial Activation in Stroke Therapy: Pharmacological Tools and Gender Effects
Current Medicinal Chemistry The NMDA Receptor/Ion Channel Complex: A Drug Target for Modulating Synaptic Plasticity and Excitotoxicity
Current Pharmaceutical Design Cannabinoids and Neuroprotection in Motor-Related Disorders
CNS & Neurological Disorders - Drug Targets